Oral AMXT 1501 Dicaprate in Combination With DFMO
Completed · Phase 1
Conditions studied: Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
In brief
A Phase 1 study will be conducted to establish safety and dose level of AMXT 1501 dicaprate alone, and in combination with DFMO, in cancer patients.
Key facts
- Study ID
- NCT03536728
- Run by
- Aminex Therapeutics, Inc.
- People needed
- 56
- Starts
- 2018-06-12
- Expected to finish
- 2023-04-21
- Last updated by the study team
- 2023-05-25
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Next Oncology - Austin Midtown — Austin, Texas, United States
- MD Anderson Cancer Center — Houston, Texas, United States
- Next Oncology - San Antonio — San Antonio, Texas, United States
- Virginia Cancer Center — Fairfax, Virginia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.